P/E at 34.74 vs Industry's 33.75: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium in Line with Sector

The current P/E of 34.74 for Sun Pharmaceutical Industries Ltd sits slightly above the Pharmaceuticals & Biotechnology industry average of 33.75. This premium, though not excessive, suggests investors are willing to pay a bit more for the stock relative to its peers. The valuation aligns with the company’s large-cap status and its historical performance track record. However, the premium is modest enough to invite questions about whether the stock’s earnings growth justifies this level — previously rated Strong Buy, what is Sun Pharma’s current rating? The four-parameter analysis factors in the valuation premium alongside other metrics.

Performance Across Timeframes: Mixed Momentum

Examining returns over various periods reveals a divergence in momentum. Over one year, Sun Pharmaceutical Industries Ltd has gained 6.75%, outperforming the Sensex’s 7.78% decline. The three-month return is also positive at 3.08%, contrasting with the Sensex’s 7.59% fall. Year-to-date, the stock is up 4.18% while the Sensex is down 11.86%. However, the one-week and one-month returns show underperformance, with the stock down 2.70% and 0.92% respectively, compared to the Sensex’s declines of 1.80% and 2.34%. This short-term weakness amid longer-term strength raises the question — is this a temporary pause or a sign of shifting market sentiment? The 3-year and 5-year returns of 81.42% and 166.90% respectively, far exceed the Sensex’s 20.32% and 44.63%, underscoring the stock’s strong historical performance.

Moving Average Configuration: A Technical Crossroad

The technical picture for Sun Pharmaceutical Industries Ltd is somewhat mixed. The stock trades above its 50-day, 100-day, and 200-day moving averages, signalling underlying strength over the medium to long term. However, it remains below the 5-day and 20-day moving averages, indicating recent short-term pressure. The 5-day and 20-day MAs often reflect immediate market sentiment, so this configuration suggests a recent pullback within a broader uptrend. The 1-day performance of -0.52% versus the Sensex’s 0.45% gain further highlights this short-term softness. The 5-day and 20-day resistance levels may be critical hurdles — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent quarters. Out of 33 stocks that declared results, 19 reported positive outcomes, 9 were flat, and 5 negative. This distribution suggests a generally favourable environment for the sector, though pockets of weakness remain. Sun Pharmaceutical Industries Ltd’s performance aligns with the sector’s positive bias, particularly over longer timeframes. The stock’s ability to outperform the Sensex and maintain a valuation premium reflects its relative strength within this competitive landscape.

Rating Reassessment: Previously Strong Buy

On 18 May 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from Strong Buy. The current Mojo Score stands at 74.0, indicating a solid standing, though the precise rating is not disclosed. This reassessment likely reflects the nuanced balance between valuation, recent price action, and sector dynamics. The stock’s large-cap status and consistent historical returns underpin its continued appeal, but the short-term technical signals and valuation premium invite closer scrutiny — should investors in Sun Pharma hold, buy more, or reconsider?

Conclusion: A Stock Balancing Valuation and Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a slight valuation premium with a strong long-term performance record. The one-year and three-month returns outpace the Sensex, but recent short-term weakness and a mixed moving average configuration suggest caution. The sector’s generally positive results provide a supportive backdrop, yet the rating reassessment from Strong Buy signals a more measured stance. Collectively, these factors highlight the importance of weighing valuation against momentum — what is the current rating for Sun Pharmaceutical Industries Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →